Company intelligence / Profile preview

Shreis Scalene Group

Gaithersburg, Maryland, United Statesshreis.org ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

CYTOTRON®, a non-invasive therapeutic medical device using QMRT platform technology to treat solid tumors and musculoskeletal disorders, has received FDA Breakthrough Device Designation based on preliminary data in multiple cancer types. CELLFORN®, a novel drug delivery platform using radio-frequency/magnetic resonance to enhance chemotherapy efficacy while reducing toxicity profiles in cancer patients is also being clinically validated. The group’s SHYCOCAN device was marketed under emergency use during COVID for virus mitigation.

Therapeutic areas: OncologyPulmonologyEndocrinologyDermatologyRheumatologyInfectious Diseases
Modalities: DeviceDrug delivery device (CELLFORN®/FORN®)
Industry: Therapeutic Medical Devices

Partnerships

Seeking partnerships with academic centers/cancer treatment centers/big pharma for clinical trials and commercialization of CYTOTRON & CELLFORN technologiesTechnology partner/inventor Dr. Rajah Vijay Kumar

Beyond the preview

Go deeper on Shreis Scalene Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shreis Scalene Group.

Explore the full profile